Rosetta Genomics discontinues testing using PCR-based assays out of Lake Forest
According to a regulatory filing, on August 22, 2016, Rosetta Genomics filed a Form 6-K announcing the receipt of a notice of rescission of conditional approval from New York State Department of Health for four of its PCR-based gene mutation assays run out of its Lake Forest, California facility. The company has since discontinued testing using those same assays. Instead, the company is exploring alternative paths to re-establish testing for these gene mutations including the potential of offering FDA-cleared versions of these assays where applicable, and revalidating these assays. During this interim period the company is satisfying its customer needs for this testing through third party laboratories.